Assuming progression is required, the following results were found.

  • Genentech Presents New Six-Year Ocrevus (Ocrelizumab) Data Which Showed That Earlier Initiation and Continuation of Treatment Reduced Disability Progression in Multiple Sclerosis

    patients who were treated with Ocrevus® (ocrelizumab) continuously for six years or more had reduced risk of disability progression in relapsing MS (RMS) and primary progressive MS (PPMS). These results suggest earlier treatment with Ocrevus reduced the...

    https://mschristian.org/index.php/blog/genentech-presents-new-six-year-ocrevus-ocrelizumab-data-which-showed-that-earlier-initiation-and-continuation-of-treatment-reduced-disability-progression-in-multiple-sclerosis
  • "Treating MS: A Simplified Strategy Boosts Patient and Provider Satisfaction"

    treatment with an effective medication, monitor the patient by listening to them, examining them to iden- tify disability progression, and reviewing serial neuroimaging. At each visit, ask the following treatment-related questions: All ambulatory...

    https://mschristian.org/index.php/blog/treating-ms-a-simplified-strategy-boosts-patient-and-provider-satisfaction
  • Disability progression in multiple sclerosis linked to income, education

    Neighbourhood income and education level is associated with risk of disability progression in patients with multiple sclerosis, suggests new research from the University of British Columbia. UBC researchers, along with colleagues in Wales, compared...

    https://mschristian.org/index.php/blog/disability-progression-in-multiple-sclerosis-linked-to-income-education
  • Study shows the progression of multiple sclerosis can be slowed

    is difficult to diagnose, and, as yet, it has no cure. However, according to new research, it may be possible to slow its progression without some of the health risks associated with current treatments. Share on PinterestNew research in mice shows a...

    https://mschristian.org/index.php/blog/study-shows-the-progression-of-multiple-sclerosis-can-be-slowed
  • Novartis receives positive CHMP opinion for Mayzent® (siponimod) for the treatment of adult patients with active secondary progressive multiple sclerosis (SPMS) | Small Molecules | News Channels - PipelineReview.com

    SPMS patient population (EDSS score 3.0 to 6.5 at baseline), showing Mayzent significantly reduced the risk of disease progression, including physical disability and cognitive decline[2]Up to 80% of patients with relapsing remitting multiple sclerosis...

    https://mschristian.org/index.php/blog/novartis-receives-positive-chmp-opinion-for-mayzent-siponimod-for-the-treatment-of-adult-patients-with-active-secondary-progressive-multiple-sclerosis-spms-small-molecules-news-channels-pipelinereview-com
  • Researchers Identify Nerve Cells That Are Vulnerable to Damage in MS

    July 18, 2019 Findings contribute to efforts to stopping MS progression SUMMARYCollaborators in Cambridge and San Francisco used advanced technology to evaluate genetic instructions within single brain cells in specific areas of brain tissues from...

    https://mschristian.org/index.php/blog/researchers-identify-nerve-cells-that-are-vulnerable-to-damage-in-ms
  • How the gut influences neurologic disease

    Researchers are identifying the key players involved in the gut-brain connection and their role in disease progression Date:Source:Brigham and Women's HospitalSummary:A study sheds new light on the connection between the gut and the brain, untangling...

    https://mschristian.org/index.php/blog/how-the-gut-influences-neurologic-disease
  • Four-Year Study Confirms That Imaging the Eye with OCT Provides Window to MS Progression in the Brain and a Way to Track the Effects of Therapies

    inexpensive and well tolerated imaging method. These findings suggest that OCT findings reflect underlying disease progression, and further validate the usefulness of OCT as an important tool for tracking MS and the impacts in clinical trials. The...

    https://mschristian.org/index.php/blog/four-year-study-confirms-that-imaging-the-eye-with-oct-provides-window-to-ms-progression-in-the-brain-and-a-way-to-track-the-effects-of-therapies
  • Genentech to Present Pivotal Data for Satralizumab in Neuromyelitis Optica Spectrum Disorder and Six-year Ocrevus (Ocrelizumab) Data in Multiple Sclerosis at ECTRIMS

    into neurofilament light chain (NfL) levels as a potential biomarker for predicting multiple sclerosis (MS) disability progression; new longer-term Ocrevus data of more than six years show reduction of disability progression in relapsing and primary...

    https://mschristian.org/index.php/blog/genentech-to-present-pivotal-data-for-satralizumab-in-neuromyelitis-optica-spectrum-disorder-and-six-year-ocrevus-ocrelizumab-data-in-multiple-sclerosis-at-ectrims
  • What to know about secondary progressive multiple sclerosis (SPMS)

    SPMS. According to the National Multiple Sclerosis Society, most people with RRMS will eventually develop a secondary progression course that involves a gradual worsening of symptoms over time. Table of contents Secondary progressive multiple sclerosis...

    https://mschristian.org/index.php/blog/what-to-know-about-secondary-progressive-multiple-sclerosis-spms-1
  • An important clue on the role of diet in MS?

    between reducing the amount of methionine (an amino acid found in animal products) in a person's diet and development and progression of MS and other disorders. The very fact that you are reading this likely means that you have heard about and/or are...

    https://mschristian.org/index.php/blog/an-important-clue-on-the-role-of-diet-in-ms
  • A molecular key for delaying the progression of Multiple Sclerosis is found

    harmful when it is prolonged over time, leading to chronic inflammation, and aggravates the disease and encourages its progression. In the work just published it was possible to identify a receptor known as P2X4 present in the microglial cells that...

    https://mschristian.org/index.php/blog/a-molecular-key-for-delaying-the-progression-of-multiple-sclerosis-is-found
  • MS: High-strength MRI may predict disease progression

    for people with multiple sclerosis (MS). The scientists used a high-strength MRI to detect lesions and evaluate the progression of the disease. They published their findings in the journal Radiology. To track the MS participants for the study, the...

    https://mschristian.org/index.php/blog/ms-high-strength-mri-may-predict-disease-progression-1
  • CMSC INforMS: Use of DMTs Changing ‘Natural History’ of Relapsing MS, Study Says

    Register for the MS Beacon Newsletter People with relapsing multiple sclerosis (MS) have a better prognosis and a slower progression to disability since the introduction of disease-modifying treatments (DMTs) some 20 years ago, according to a...

    https://mschristian.org/index.php/blog/cmsc-informs-use-of-dmts-changing-natural-history-of-relapsing-ms-study-says
  • SPMS and Diet: What Foods Can Help?

    Many treatments for multiple sclerosis (MS) are targeted at reducing inflammation, thereby slowing progression of the autoimmune disease. An anti-inflammatory diet also may slow disease progression, as well as enhance the positive effects of...

    https://mschristian.org/index.php/blog/spms-and-diet-what-foods-can-help
  • Siponimod Delays Time to Wheelchair in Secondary Progressive MS - Neurology Times

    of Lille, at ECTRIMS 2019, September 11-13 in Stockholm, Sweden. “Siponimod has been shown to reduce disability progression, not only physically based on Expanded Disability Status Scale [EDSS], but also reduced cognitive decline in a typical secondary...

    https://mschristian.org/index.php/blog/siponimod-delays-time-to-wheelchair-in-secondary-progressive-ms-neurology-times
  • Multiple sclerosis treatments delay progression of the disease

    and University of Melbourne-led study is the first to provide evidence that the currently available therapies can delay progression of disability in Multiple Sclerosis. It showed that early treatment -- particularly within five years of onset -- delayed...

    https://mschristian.org/index.php/blog/multiple-sclerosis-treatments-delay-progression-of-the-disease
  • New research to stop Multiple Sclerosis - WILX-TV

    MI. (WILX) - Dr. Rany Aburashed at Memorial Healthcare in Owosso is conducting new research to potentially stop the progression of Multiple Sclerosis. A woman who witnessed the struggles of Multiple Sclerosis (MS) in a family member is now battling the...

    https://mschristian.org/index.php/blog/new-research-to-stop-multiple-sclerosis-wilx-tv
  • Research Project 3TR To Use Breath Biopsy, Improve Immune-mediated Disease Management - Technology Networks

    globe and pose a substantial burden to healthcare systems. While different treatments are available, response and disease progression in individual patients remain unpredictable, which can hamper the management of their disease. In a never-before-seen...

    https://mschristian.org/index.php/blog/research-project-3tr-to-use-breath-biopsy-improve-immune-mediated-disease-management-technology-networks
  • #ECTRIMS2019 - Are Injectables Inappropriate for Active Relapsing MS? - Multiple Sclerosis News Today

    with first-line injectables, offer benefits in several clinical outcomes, namely annual relapse rates, disability progression, treatment resistance, and health-related quality of life. With more high-efficacy therapies becoming available, is it now...

    https://mschristian.org/index.php/blog/ectrims2019-are-injectables-inappropriate-for-active-relapsing-ms-multiple-sclerosis-news-today

Results 1 - 20 of 80
 
 

Follow Us on Twitter

Follow Us On Twitter - Image